Cancer Research Technology Limited

Astex Therapeutics Limited

Otsuka Pharmaceutical Company, Limited

Taiho Pharmaceutical Company Limited

Jeffrey David St Denis

Steven Howard

Christopher Norbert Johnson

Kim Louise Hirst

James Daniel Osborne

Rhian Sara Holvey

Gianni Chessari

Ildiko Maria Buck

Benjamin David Cons

Bernard Thomas Golding

David Charles Rees

Ian Robert Hardcastle

Emiliano Tamanini

Dale Robert Mitchell

Celine Florence Cano

Joanne Peach

Duncan Charles Miller

David Wyn Watson

Martin Edward Mäntylä Noble

Arwel Lewis

Benjamin Paul Whittaker

Roger John Griffin

James Edward Harvey Day

Brian Christopher Bishop

Steven Douglas Hiscock

Darren James Dixon

John Walter Liebeschuetz

Jonas Calleja Priede

Aaron Michael Dumas

David Parry-Jones

Meenakshi Sundaram Shanmugham

Matthew James Gaunt

Charlotte Mary Griffiths-Jones

Andrew James Woodhead

Takahiro Ogawa

Tadashi Shimamura

Ryo Kato

Jeremy Peter Scott

Christopher Charles Frederick Hamlett

David Cousin

Takashi Mita

Nicholas John Palmer

Hideto Fujiwara

David John Nash

Peter Richard Mullens

Alan Richard Burns

Yufu Sagara

Risako Miura

Isabelle Anne Lemasson

Nicholas Paul Richards

Guillaume François Parra

David Geoffrey Twigg

James Edward Day

Sarah Cully

The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them

The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity

The invention provides a compound of formula (I):

Heterobicyclic compounds for inhibiting the activity of SHP2

The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Pharmaceutical compounds

Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity

Growing community of inventors

Cambridge, United Kingdom

Jeffrey David St Denis